Publications

In Vitro Activity of Omadacycline and Comparator Agents Against 485 Infrequently Encountered Bacterial Pathogens from the SENTRY Surveillance Programme. Lead author: Michael Huband. ECCMID 2023, April 15-18, Copenhagen.

Cefiderocol In Vitro Activity Against Molecularly Characterized Acinetobacter baumannii-calcoaceticus complex and Pseudomonas aeruginosa Clinical Isolates Causing Infection in Europe and Adjacent Regions (2020–2021). Lead author: Rodrigo Mendes. ECCMID 2023, April 15-18, Copenhagen.

Comparison of In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Carbapenem-resistant Enterobacterales Clinical Isolates Causing Infections in Europe and Surrounding Regions (2020–2021). Lead author: Dee Shortridge, ECCMID 23, April 15-18, Copenhagen.

In Vitro Activity of Manogepix and Comparators against 610 Infrequently Encountered Yeast and Mould Isolates from the SENTRY Surveillance Program (2017–2022). Lead author: Michael Huband, ECCMID 2023, April 15-18, Copenhagen.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter spp. Causing Infections in Europe and Adjacent Regions. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia, Including Carbapenem-Resistant Isolates from the SENTRY Antimicrobial Surveillance Program (2020–2022)

Rezafungin Activity against Candida and Aspergillus Isolates Causing Invasive Infections in European Medical Centres (2019–2021). Lead author: Cecilia Carvalhaes. ECCMID 2023, April 15-18, 2023, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Isolates of Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Antimicrobial Activity of Aztreonam-Avibactam against Gram-negative Bacteria Isolated from Patients Hospitalised with Pneumonia in European Medical Centres (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

In vitro activity of gepotidacin against Escherichia coli causing urinary tract infections between 2019–2021 in Europe, Russia, Israel, and Turkey, including molecularly characterized fluoroquinolone-resistant subsets. Lead author: Rodrigo Mendes, ECCMID 2023, April 15-18, Copenhagen.

In vitro Activity of Novel Compound RG6006 Against Clinical Isolates of Acinetobacter baumannii-calcoaceticus complex in the Presence of 20% Human Serum. Lead author: Dee Shortridge. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

In Vitro Activity of Bacteriophage Cocktail Tested Against Pseudomonas aeruginosa Cystic Fibrosis Isolates. Lead author: Timothy Doyle. ECCMID, April 15-18, Copenhagen.

VITEK2 Advanced Expert System β-Lactam Resistance Phenotyping Compared to Whole Genome Sequencing in Enterobacterales Isolates from European Medical Centres. Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, Copenhagen.

Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Bloodstream Infections from Europe, Asia, and Latin America (2020–2021). Lead author: Helio Sader, ECCMID 2023, April 15-18, Copenhagen.

Trends on the Activity of Mould-active Agents Against Aspergillus fumigatus Clinical Isolates With and Without Cyp51 Alterations
from Europe and North America (2017–2021). Lead author: Cecilia Carvalhaes. Presented at ECCMID 23, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against European Enterobacterales, Including Carbapenem-Resistant Isolates, From the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Rezafungin Activity against Candidemia isolates collected from European medical centres (2019–2021). Lead author: Cecilia Carvalhaes. Presented at ECCMID 2023, April 15-18, 2023, Copenhagen.

Enterobacter hormaechei Carrying blaNDM Predominates Among Carbapenem-resistant Enterobacter spp. Collected During the SENTRY Antimicrobial Surveillance Program (2016–2021). Lead author: Hank Kimbrough.

Bloodstream Infections in Europe and United States: Aetiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Helio Sader. Presented at ECCMID 2023, April 15-18, Copenhagen.

Comparison of Cefiderocol and Cefepime-Taniborbactam Activities against Resistant Subgroups of Enterobacterales and Pseudomonas aeruginosa, and Cefiderocol and Sulbactam-Durlobactam Against Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex. Lead Author: Dee Shortridge, ECCMID 2023, April 15-18, Copenhagen.

Activity of Cefiderocol and Comparator Agents against US Enterobacterales, Including Carbapenem-Resistant Isolates, from the SENTRY Antimicrobial Surveillance Program (2020–2022). Lead author: Dee Shortridge, ECCMID, April 15-18, Copenhagen.

Recent Increase in Fluconazole-Nonsusceptible Candida parapsilosis in a Global Surveillance with the Expansion of the Erg11 Y132F genotype and a Rapid Detection Method to Detect This Alteration. Lead Author: Mariana Castanheira, ECCMID 2023, April 15-18, Copenhagen.

Aztreonam/avibactam activity against a large collection of carbapenem-resistant Enterobacterales (CRE) collected in hospitals from Europe, Asia and Latin America (2019–21) by HS Sader, M Castanheira, JH Kimbrough, V Kantro, RE Mendes in J. Antimicrob. Chemother. 5(3):2023, dlad032.

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug resistant Enterobacterales from United States Medical Centers (2018−2022) by HS Sader, RE Mendes, L Duncan, JH Kimbrough, CG Carvalhaes, and M Castanheira in Diagn Microbiol Infect Dis 2023; 106, 115945.

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific by CG Carvalhaes, PR Rhomberg, MD Huband, MA Pfaller, and M Castanheira in J of Fungi 2023; 9, jof9020241.

Contemporary molecular epidemiology of Escherichia coli causing urinary tract infections in the United States and in vitro activity of tebipenem and comparators against various genetic subsets (2018-2020) by RE Mendes, SJ Ryan Arends, JM Streit, I Critchley, N Cotroneo, and M Castanheira in Microbiol Spectrum 2023; 11(1), 2057-22.

Antimicrobial activity of ceftibuten-avibactam against a global collection of Enterobacterales from patients with complicated urinary tract infections by HS Sader, CG Carvalhaes, MD Huband, RE Mendes, and M Castanheira in Eur J Clin Microbiol Infect Dis. 2023; 42(2), 453-459.

Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021) by HS Sader, RE Mendes, SJ Ryan Arends, CG Carvalhaes, D Shortridge, and M Castanheira in Int J Antimicrob Agents 2023; 61(4): 106744.

In vitro Activity of Ceftaroline Against an International Collection of Kingella kingae Isolates Recovered From Carriers and Invasive Infections by JM Maher, RE Mendes, HK Huynh, EA Porsch, JW St Greme III, P Yagupsky, and J Bradley in Pediatr Infect Dis 2023; 42(3), 206-2011.

Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers by HS Sader, RE Mendes, JH Kimbrough, V Kantro, and M Castanheira in Open Forum Infect Dis 2023; 10 (2), ofad058.

Trends of β-Lactamase Occurrence Among Escherichia coli and Klebsiella pneumoniae in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by β-Lactamase Type by M Castanheira, JH Kimbrough, S DeVries, RE Mendes, and HS Sader in Open Forum Infect Dis 10(2): 2023, ofad038.

Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales From United States Hospitals and the Activity of Aztreonam-Avibactam Against Contemporary Enterobacterales (2019–2021) by HS Sader, RE Mendes, CG Carvalhaes, JH Kimbrough, M Castanheira in Open Forum Infect Dis 10.2 (2023), ofad046.

Performance of the Vitek 2 Advanced Expert System (AES) as a Rapid Tool for Reporting Antimicrobial Susceptibility Testing (AST) in Enterobacterales from North and Latin America by CG Carvalhaes, D Shortridge, LN Woosley, N Gurung, and M Castanheira in Microbiol Spectr 11(1): 2023, 046673-22.

Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific by CG Carvalhaes, PR Rhomberg, MD Huband, MA Pfaller, and M Castanheira in J Fungi (Basel) 9: 241, 2023.

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-Avibactam Generates Diverse Resistance Mechanisms by M Castanheira, J Lindley, TB Doyle, AP Davis, HS Sader in Int J Antimicrob 61 (2023), 106698.

The plethora of resistance mechanisms in Pseudomonas aeruginosa: transcriptome analysis reveals a potential role of lipopolysaccharide pathway proteins to novel β-lactam/ β-lactamase inhibitor combinations by M Castanheira, TB Doyle, CM Hubler, TD Collingsworth, S DeVries, RE Mendes in J Glob Antimicrob Resist 31 (2022), 72-79.

Update on the in vitro activity of ceftaroline against Staphylococcus aureus from United States (US) medical centers stratified by infection type (2018-2020) by HS Sader, M Castanheira, LR Duncan, RE Mendes in Diagn Microbiol Infect Dis 105:1 (2023), 115820.

Activities of Manogepix and Comparators against 1,435 Recent Fungal Isolates Collected during an International Surveillance Program (2020) by MA Pfaller, MD Huband, PR Rhomberg, PA Bien, and M Castanheira in Antimicrob Agents Chemother 66:100 (2022), aac.01028-22.

Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals. Lead Author: Rodrigo E. Mendes. Presented at IDWeek 2022, October 19-23, Washington DC.

Multicentre validation of a modified EUCAST MIC testing method and development of associated epidemiologic cut-off (ECOFF) values for rezafungin by Arendrup MC, Arikan-Akdagli S, Castanheira M, Guinea J, Locke JB, Meletiadis J, Zaragoza O in J. Antimicrob. Chemother. (2022); dkac373.

In vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020) by Mendes RM, Hubler C, Kimbrough JH, Critchley I, Cotroneo N, Castanheira in Antimicrob. Agents Chemother. 66:10 (2022); aac.01214-22.

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018–19) by Sader HS, Mendes RE, Duncan LR, Carvalhaes CG, and Castanheira M in J. Antimicrob. Chemother. 77 (2022); 2642-2649.

Evaluation of the Post-Antifungal Effect of Rezafungin and Micafungin against Candida albicans, Candida parapsilosis and Candida glabrata by Carvalhaes CG, Rhomberg PR, Pfaller MA, Locke JB, Castanheira M in Mycoses 65 (2022); 1040-1044.

Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other
β-Lactam Agents. Lead author: Mariana Castanheira. IDWeek 2022. October 19-21. Washington DC.

Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.

In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals. Lead author: Rodrigo Mendes. Presented at IDWeek 2022. October 19-21, 2022. Washington DC.

Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units
in US Medical Centers (2010–2019). Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.

Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.

Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.